Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Ivabradine Zentiva, ivabradine, Date of authorisation: 11/11/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Coagadex, human coagulation factor X, Date of authorisation: 16/03/2016, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

PSUSA/00002139/202411

Type-II variations: questions and answers

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 21, Status: Authorised

PSUSA/00002036/202411

PSUSA/00002011/202412